The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.
Get full access to this article
View all access options for this article.
References
1.
OgataYShimokawaMTanakaT. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol. 2016;21(2):335-343.
2.
MunemotoYKandaMIshibashiK. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015;15:786.
3.
FeliuJSaludASafontMJ. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer. 2014;111(2):241-248.
4.
HongYSLeeSSKimK. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Am J Clin Oncol. 2014;37(1):19-23.
5.
Díaz-RubioEGómez-EspañaAMassutiB. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15-25.
6.
JacksonCGSharplesKThompsonPI. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer. 2014;14:737.
7.
VamvakasLMatikasAKarampezisA. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer. 2014;14:277.
8.
WongNSFernandoNHBendellJC. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(3):210-216.
9.
SnoerenNVoestEEBergmanAM. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CapOx) vs CapOx alone as adjuvant treatment. BMC Cancer. 2010;10:545.
10.
GulhatiPRaghavKShroffRT. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: a single-center, open-label, phase 2 study. Cancer. 2016;123(6):1011-1017. doi:10.1002/cncr.30445.http://onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf. Accessed June 7, 2017.
11.
National Cancer Comprehensive Network. NCCN clinical practice guidelines—colon cancer. Version 2.2017. http://www.nccn.org. Accessed February 2017.
12.
National Cancer Comprehensive Network. NCCN clinical practice guidelines—rectal cancer. Version 2.2017. http://www.nccn.org. Accessed February 2017.
13.
HeskethPJKrisMGGrunbergSM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103-109.
HeskethPJBohlkeKLymanGH. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34(4):381-386.
16.
Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. 2016. Version.1.2. Accessed February 2017.
17.
GelingOEichlerHG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294.
18.
TerreyJPAaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996;8:281-288.
19.
CarmichaelJKeizerHJCupissolD. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9(5):381-385.
20.
de WitRde BoerACvd LindenGH. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-1101.
21.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993;119(6):350-354.
22.
SoukopM. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177-183.
23.
BrandiGPantaleoMAGalliC. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89(3):477-481.
24.
DoldFHoeyDCarberyM. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Proc Am Soc Clin Oncol. 2002;21:1478.
25.
QureshiKMLeichmanCBerdzikJ. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. Proc Am Soc Clin Oncol. 2003;22:789.
26.
SmithTJKhatcheressianJLymanGH. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
MarounJAAnthonyLBBlaisN. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14(1):13-20.
29.
BensonABAjaniJACatalanoRB. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926.
30.
GamelinEGamelinLBossiL. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29(suppl 15):21-33.
GrotheyANikcevichDASloanJA. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29(4):421-427.
34.
LoprinziCLQinRDakhilSR. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32(10):997-1005.
35.
PooleCGardinerJTwelvesC. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002;49(3):225-234.
TakimotoCHRemickSCSharmaS. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 2003;21(14):2664-2672.
ShahabIPattersonWP. Renal and electrolyte abnormalities due to chemotherapy. In: PerryMC ed. The Chemotherapy Sourcebook. 4th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2008;223-233.
TwelvesCGlynne-JonesRCassidyJ. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5(7):1696-1702.
42.
DoroshowJHSynoldTWGandaraD. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003;30(suppl 15):14-19.
43.
Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinsuoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460-446.
